Educational research platform — not medical or investment advice. Verify all data before decisions.

GIP / GLP-1 / glucagon triple agonist

Retatrutide

Also known as LY3437943.

Stage Phase 3
Indications Obesity, Type 2 Diabetes, MASH
Last updated:Jul 15, 2026Source:ClinicalTrials.gov + sponsor pipeline pagesVerified:Manually reviewedData provider:PeptidePlanet Research

Mechanism

Triagonist targeting three incretin/hormone receptors under investigation.

Educational summary. Not medical advice. See sponsor materials and peer-reviewed literature for full pharmacology.

Companies developing it

1

Related trials

1

Current research

Data unavailable
Curated peer-reviewed research links launch once our editorial pipeline is verified.

Safety summary

Data unavailable
Safety summaries require a verified regulatory data source and clinical review. Consult the FDA label and sponsor prescribing information for approved products.

More peptides

Semaglutide

GLP-1 receptor agonist

Approved

Tirzepatide

Dual GIP / GLP-1 receptor agonist

Approved

Survodutide

GLP-1 / glucagon dual agonist

Phase 3

Cagrilintide

Long-acting amylin analog

Phase 3